Category: News

DRI Healthcare Trust Announces Sale of its TZIELD™ Royalty Interest to Sanofi for US$210 Million and Announces a US$20 Million Special Cash Distribution to Unitholders

– Transaction will allow DHT to redeploy capital into new deals generating compounding returns for unitholders – TORONTO, April 27, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“the Trust”) announces that its wholly-owned subsidiary has sold its royalty interest and milestone payment obligations in the worldwide sales of TZIELD™ to a subsidiary […]

DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of TZIELD™ (teplizumab-mzwv) and Updates Long-Term Cash Receipts Outlook

– Transaction adds a ground-breaking type 1 diabetes therapy to DRI’s expanding portfolio – – Excluding any new transactions, DRI now expects 2030 cash receipts to be at least as high as 2022 cash receipts – – Extends DRI’s overall portfolio duration to over 10 years – TORONTO, March 8, 2023 /CNW/ – DRI Healthcare […]

DRI Healthcare Trust Reports Fourth Quarter and Fiscal 2022 Results

– 2022 deployment of US$281 million continues to validate growth strategy – – Continued strong performance of existing assets and financial results – TORONTO, March 1, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022. […]

DRI Healthcare Trust Announces US$95 million Private Placement of Preferred Securities and Increased Deployment Target

– Provides additional capital to fund biopharmaceutical research, driving value for DRI’s unitholders and partners –  TORONTO, Feb. 8, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that it has completed a private placement of US$95 million of preferred securities (the “Private Placement”) to an investor group that […]